Status:
UNKNOWN
Immune Profiling of COVID19-patients Admitted to ICU
Lead Sponsor:
Hamad Medical Corporation
Collaborating Sponsors:
Qatar University
Weill Cornell Medical College in Qatar
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
SARS-CoV-2 is the novel coronavirus responsible for COVID-19, coronavirus disease 2019. This new coronavirus was first detected in Wuhan, China in late December 2019. According to WHO, the incidence r...
Eligibility Criteria
Inclusion
- Admitted to ICU for suspicious COVID-19
- Signed consent form
Exclusion
- Immuno-compromised or immuno-deficient patients
- Diagnosed with any immunological disorders, cancer, and onco-hematological diseases at the inclusion date
- Patients under treatment or treated within 5 years before inclusion or at the end of chemotherapy within the 6 months prior to inclusion date
- Patients under any immune-suppressive medications, antibody therapy, corticosteroids, bone marrow transplant under the last 6 months of inclusion
- Unsigned consent form
Key Trial Info
Start Date :
April 27 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2022
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04473131
Start Date
April 27 2020
End Date
June 1 2022
Last Update
July 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamad Medical Corporation
Doha, Qatar